MetaStat Inc (MTST)
MetaStat Inc. is a Boston-based healthcare company focused on precision medicine for cancer. The company develops therapeutic and diagnostic solutions designed to identify and address the MENA pathway, which it describes as a key driver of metastasis, treatment resistance, and cancer progression in solid tumors. Its pipeline includes the MENA diagnostic assay, a tissue-based quantitative immunofluorescence test, companion diagnostics intended to help assess responses to RTK inhibitor and anti-microtubule therapies, a liquid blood-based biopsy concept aimed at improving cancer detection and patient care, and the MetaSite Breast assay, an immunohistochemistry test related to tumor microenvironment sites. MetaStat also states that it is developing a prognostic diagnostic to help estimate metastatic risk. The company’s common stock trades on OTC Markets under the symbol MTST.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-MTST
|
—
|
—
|
—
|
—
|
—
|
—
|
Great
|
—
|
—
|
—
|
0.0%
|
—
|
—
|
—
|
—
|
5.877 K
|
—
|
—
|
—
|
—
|
—
|
—
|